- Home
- RNA
as 12-18-2024 11:42am EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.4B | IPO Year: | 2020 |
| Target Price: | $63.60 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.37 - $56.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | $10,117,000 | Revenue Growth: | -0.19% |
| Revenue Growth (this year): | -10.33% | Revenue Growth (next year): | -19.44% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flanagan W. Michael | RNA | CSTO | Dec 11 '24 | Sell | $35.77 | 24,000 | $858,400.80 | 85,389 | |
| LEVIN ARTHUR A | RNA | Director | Nov 19 '24 | Sell | $42.12 | 3,323 | $139,972.74 | 14,830 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Nov 18 '24 | Sell | $41.14 | 25,000 | $1,028,520.00 | 94,018 | |
| MacLean Michael F | RNA | Chief Financial Officer | Nov 6 '24 | Sell | $45.63 | 106,319 | $4,843,979.06 | 94,093 | |
| LEVIN ARTHUR A | RNA | Director | Oct 21 '24 | Sell | $46.63 | 5,000 | $233,167.50 | 14,830 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Oct 16 '24 | Sell | $48.52 | 25,000 | $1,213,010.00 | 94,018 | |
| Thompson Tamar | RNA | Director | Oct 7 '24 | Sell | $44.98 | 30,000 | $1,349,259.00 | 0 | |
| Flanagan W. Michael | RNA | CSTO | Oct 1 '24 | Sell | $47.62 | 62,500 | $2,976,112.50 | 85,389 | |
| Boyce Sarah | RNA | President and CEO | Sep 19 '24 | Sell | $44.00 | 32,880 | $1,446,723.29 | 234,663 | |
| LEVIN ARTHUR A | RNA | Director | Sep 19 '24 | Sell | $45.73 | 5,000 | $228,658.00 | 14,830 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
PR Newswire
22 days ago
Avidity Biosciences to Participate in Upcoming Investor Conference
MT Newswires
22 days ago
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
PR Newswire
a month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Zacks
a month ago
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Investor's Business Daily
a month ago
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
PR Newswire
a month ago
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Simply Wall St.
a month ago
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.